Predicted protein targets (top 12)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | TP53 | P04637 | 1/20 | 0.54 |
| ▸ | MEN1 | O00255 | 4/20 | 0.49 |
| ▸ | KMT2A | Q03164 | 4/20 | 0.49 |
| ▸ | TNF | P01375 | 1/20 | 0.48 |
| ▸ | SMN1; SMN2 | Q16637 | 2/20 | 0.48 |
| ▸ | NPSR1 | Q6W5P4 | 1/20 | 0.48 |
| ▸ | PDE4A | P27815 | 4/20 | 0.47 |
| ▸ | PDE4B | Q07343 | 4/20 | 0.47 |
| ▸ | PDE4C | Q08493 | 4/20 | 0.47 |
| ▸ | PDE4D | Q08499 | 4/20 | 0.47 |
| ▸ | MAPT | P10636 | 2/20 | 0.45 |
| ▸ | ALOX15 | P16050 | 1/20 | 0.45 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL6289221 | 1.00 | TP53 (0.54) | TP53MEN1KMT2ATNFSMN1; SMN2 | |
| SCHEMBL6286599 | 1.00 | TP53 (0.54) | TP53MEN1KMT2ATNFSMN1; SMN2 | |
| SCHEMBL6283428 | 0.90 | TP53 (0.56) | TP53MEN1KMT2ATNFSMN1; SMN2 | |
| SCHEMBL6286610 | 0.90 | TP53 (0.56) | TP53MEN1KMT2ATNFSMN1; SMN2 | |
| SCHEMBL4857855 | 0.90 | TP53 (0.56) | TP53MEN1KMT2ATNFSMN1; SMN2 | |
| SCHEMBL6285246 | 0.89 | TP53 (0.57) | TP53MEN1KMT2ATNFPDE4A | |
| SCHEMBL6288909 | 0.89 | TP53 (0.57) | TP53MEN1KMT2ATNFPDE4A | |
| SCHEMBL4857900 | 0.89 | TP53 (0.57) | TP53MEN1KMT2ATNFPDE4A | |
| SCHEMBL4856275 | 0.88 | TP53 (0.60) | TP53MEN1KMT2ATNFPDE4A | |
| SCHEMBL6287582 | 0.88 | TP53 (0.60) | TP53MEN1KMT2ATNFPDE4A |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 9 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| EP-0800514-B1 | SUBSTITUTED IMIDES AS TNF INHIBITORS | CELGENE CORP (US) | 2006-08-23 | — | — | EP | claimed |
| US-6429221-B1 | INHIBITORS OF TUMOR NECROSIS FACTOR; USED TO TREAT CACHEXIA, ENDOTOXIC SHOCK, AND RETROVIRUS REPLICATION | CELGENE CORPORATION | 2002-08-06 | — | — | US | claimed |
| US-7329761-B2 | Substituted imides | CELGENE CORPORATION (US) | 2008-02-12 | — | — | US | disclosed |
| US-20050090516-A1 | Novel substituted imides | MULLER GEORGE W (US) | 2005-04-28 | — | — | US | disclosed |
| US-6844359-B2 | Substituted imides | CELGENE CORPORATION (US) | 2005-01-18 | — | — | US | disclosed |
| US-20020143027-A1 | Novel substituted imides | MULLER GEORGE W (US) | 2002-10-03 | — | — | US | disclosed |
| US-6429221-B1 | INHIBITORS OF TUMOR NECROSIS FACTOR; USED TO TREAT CACHEXIA, ENDOTOXIC SHOCK, AND RETROVIRUS REPLICATION | CELGENE CORPORATION | 2002-08-06 | — | — | US | disclosed |
| EP-0800514-A1 | SUBSTITUTED IMIDES AS TNF INHIBITORS | CELGENE CORPORATION (US) | 1997-10-15 | — | — | EP | disclosed |
| WO-1996020926-A1 | SUBSTITUTED IMIDES AS TNF INHIBITORS | CELGENE CORPORATION (US) | 1996-07-11 | — | — | WO | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (2 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20020143027-A1 | Novel substituted imides | TNF, MIF, TNFRSF1A | TP53 481/4885MEN1 3818/4885KMT2A 1655/4885 |
| US-20050090516-A1 | Novel substituted imides | TNF, MIF, TNFRSF1A | TP53 496/4885MEN1 3883/4885KMT2A 1420/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.